Tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy

Published on 01 Aug 2024
Last Updated on 17 Feb 2025

Guidance Recommendations

The Ministry of Health's Drug Advisory Committee has recommended:

• Tisagenlecleucel cells dispersion for infusion for treating patients 18 years of age and above with relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy.

Funding status

Tisagenlecleucel cells dispersion for infusion is recommended for inclusion on the MOH Cell, Tissue and Gene Therapy Product (CTGTP) List for the abovementioned indication from 1 August 2024.

Tisagenlecleucel should be used in line with the additional clinical criteria listed in the Annex.

Tisagenlecleucel for relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy (1 Aug 24) [PDF, 217 KB]

PES Chimeric antigen receptor T-cell therapies for relapsed or refractory large B-cell-lymphoma (updated 17 Feb 2025) [PDF, 106 KB]